Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, killing cancer cells and enhancing the effects of drugs like enzalutamide. They also disrupt the cancer’s energy system, striking it on multiple fronts. This breakthrough could open a new path to overcoming drug resistance in advanced prostate cancer.